Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia

Luca Maurillo, Francesco Buccisano, Alfonso Piciocchi, Maria Ilaria Del Principe, Chiara Sarlo, Ambra Di Veroli, Paola Panetta, Maria Irno-Consalvo, Daniela Nasso, Concetta Ditto, Marco Refrigeri, Gottardo De Angelis, Raffaella Cerretti, William Arcese, Giuseppe Sconocchia, Francesco Lo-Coco, Sergio Amadori, Adriano Venditti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission after treatment with SDAC (n=78) or HDAC (n=52) plus etoposide and daunorubicin. Consolidation consisted of intermediate-dose ARA-C and daunorubicin. MRD negativity was significantly more frequent in the SDAC vs. HDAC arm after both induction (37% vs. 15%, P=0.007) and consolidation (44% vs. 18%, P=0.002). Respective median residual leukemic cell counts with SDAC and HDAC use were 1.5 × 10-3 and 4 × 10-3 (P=0.033) after induction and 5.7 × 10-4 and 2.9 × 10-3 (P=0.008) after consolidation. Based on ARA-C schedule and post-consolidation MRD status, the four patient groups (SDAC-MRD-, HDAC-MRD-, SDAC-MRD+, and HDAC-MRD+) displayed 5-year overall survival rates of 60%, 33%, 24%, and 42% (P=0.007), respectively, with 24%, 35%, 74%, and 48% (P

Original languageEnglish
Pages (from-to)125-131
Number of pages7
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Biomarkers
Daunorubicin
Etoposide
Appointments and Schedules
Flow Cytometry
Survival Rate
Cell Count

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Maurillo, L., Buccisano, F., Piciocchi, A., Del Principe, M. I., Sarlo, C., Di Veroli, A., ... Venditti, A. (2015). Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. American Journal of Hematology, 90(2), 125-131. https://doi.org/10.1002/ajh.23893

Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. / Maurillo, Luca; Buccisano, Francesco; Piciocchi, Alfonso; Del Principe, Maria Ilaria; Sarlo, Chiara; Di Veroli, Ambra; Panetta, Paola; Irno-Consalvo, Maria; Nasso, Daniela; Ditto, Concetta; Refrigeri, Marco; De Angelis, Gottardo; Cerretti, Raffaella; Arcese, William; Sconocchia, Giuseppe; Lo-Coco, Francesco; Amadori, Sergio; Venditti, Adriano.

In: American Journal of Hematology, Vol. 90, No. 2, 01.02.2015, p. 125-131.

Research output: Contribution to journalArticle

Maurillo, L, Buccisano, F, Piciocchi, A, Del Principe, MI, Sarlo, C, Di Veroli, A, Panetta, P, Irno-Consalvo, M, Nasso, D, Ditto, C, Refrigeri, M, De Angelis, G, Cerretti, R, Arcese, W, Sconocchia, G, Lo-Coco, F, Amadori, S & Venditti, A 2015, 'Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia', American Journal of Hematology, vol. 90, no. 2, pp. 125-131. https://doi.org/10.1002/ajh.23893
Maurillo, Luca ; Buccisano, Francesco ; Piciocchi, Alfonso ; Del Principe, Maria Ilaria ; Sarlo, Chiara ; Di Veroli, Ambra ; Panetta, Paola ; Irno-Consalvo, Maria ; Nasso, Daniela ; Ditto, Concetta ; Refrigeri, Marco ; De Angelis, Gottardo ; Cerretti, Raffaella ; Arcese, William ; Sconocchia, Giuseppe ; Lo-Coco, Francesco ; Amadori, Sergio ; Venditti, Adriano. / Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. In: American Journal of Hematology. 2015 ; Vol. 90, No. 2. pp. 125-131.
@article{53fa7ddcd95d49ec9572ad9f12697025,
title = "Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia",
abstract = "We assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission after treatment with SDAC (n=78) or HDAC (n=52) plus etoposide and daunorubicin. Consolidation consisted of intermediate-dose ARA-C and daunorubicin. MRD negativity was significantly more frequent in the SDAC vs. HDAC arm after both induction (37{\%} vs. 15{\%}, P=0.007) and consolidation (44{\%} vs. 18{\%}, P=0.002). Respective median residual leukemic cell counts with SDAC and HDAC use were 1.5 × 10-3 and 4 × 10-3 (P=0.033) after induction and 5.7 × 10-4 and 2.9 × 10-3 (P=0.008) after consolidation. Based on ARA-C schedule and post-consolidation MRD status, the four patient groups (SDAC-MRD-, HDAC-MRD-, SDAC-MRD+, and HDAC-MRD+) displayed 5-year overall survival rates of 60{\%}, 33{\%}, 24{\%}, and 42{\%} (P=0.007), respectively, with 24{\%}, 35{\%}, 74{\%}, and 48{\%} (P",
author = "Luca Maurillo and Francesco Buccisano and Alfonso Piciocchi and {Del Principe}, {Maria Ilaria} and Chiara Sarlo and {Di Veroli}, Ambra and Paola Panetta and Maria Irno-Consalvo and Daniela Nasso and Concetta Ditto and Marco Refrigeri and {De Angelis}, Gottardo and Raffaella Cerretti and William Arcese and Giuseppe Sconocchia and Francesco Lo-Coco and Sergio Amadori and Adriano Venditti",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/ajh.23893",
language = "English",
volume = "90",
pages = "125--131",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia

AU - Maurillo, Luca

AU - Buccisano, Francesco

AU - Piciocchi, Alfonso

AU - Del Principe, Maria Ilaria

AU - Sarlo, Chiara

AU - Di Veroli, Ambra

AU - Panetta, Paola

AU - Irno-Consalvo, Maria

AU - Nasso, Daniela

AU - Ditto, Concetta

AU - Refrigeri, Marco

AU - De Angelis, Gottardo

AU - Cerretti, Raffaella

AU - Arcese, William

AU - Sconocchia, Giuseppe

AU - Lo-Coco, Francesco

AU - Amadori, Sergio

AU - Venditti, Adriano

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission after treatment with SDAC (n=78) or HDAC (n=52) plus etoposide and daunorubicin. Consolidation consisted of intermediate-dose ARA-C and daunorubicin. MRD negativity was significantly more frequent in the SDAC vs. HDAC arm after both induction (37% vs. 15%, P=0.007) and consolidation (44% vs. 18%, P=0.002). Respective median residual leukemic cell counts with SDAC and HDAC use were 1.5 × 10-3 and 4 × 10-3 (P=0.033) after induction and 5.7 × 10-4 and 2.9 × 10-3 (P=0.008) after consolidation. Based on ARA-C schedule and post-consolidation MRD status, the four patient groups (SDAC-MRD-, HDAC-MRD-, SDAC-MRD+, and HDAC-MRD+) displayed 5-year overall survival rates of 60%, 33%, 24%, and 42% (P=0.007), respectively, with 24%, 35%, 74%, and 48% (P

AB - We assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission after treatment with SDAC (n=78) or HDAC (n=52) plus etoposide and daunorubicin. Consolidation consisted of intermediate-dose ARA-C and daunorubicin. MRD negativity was significantly more frequent in the SDAC vs. HDAC arm after both induction (37% vs. 15%, P=0.007) and consolidation (44% vs. 18%, P=0.002). Respective median residual leukemic cell counts with SDAC and HDAC use were 1.5 × 10-3 and 4 × 10-3 (P=0.033) after induction and 5.7 × 10-4 and 2.9 × 10-3 (P=0.008) after consolidation. Based on ARA-C schedule and post-consolidation MRD status, the four patient groups (SDAC-MRD-, HDAC-MRD-, SDAC-MRD+, and HDAC-MRD+) displayed 5-year overall survival rates of 60%, 33%, 24%, and 42% (P=0.007), respectively, with 24%, 35%, 74%, and 48% (P

UR - http://www.scopus.com/inward/record.url?scp=84921361335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921361335&partnerID=8YFLogxK

U2 - 10.1002/ajh.23893

DO - 10.1002/ajh.23893

M3 - Article

C2 - 25377359

AN - SCOPUS:84921361335

VL - 90

SP - 125

EP - 131

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -